News Snapshot:
Immunotherapy developer Tevogen (TVGN) plans to go public through a merger with SPAC Semper Paratus Acquisition Corp. (NASDAQ:LGST), with the deal estimating the enterprise value of the combined company at around $1.2B. The deal is expected to close in Q4, with shares of the combined company anticipated to trade on NYSE under the symbol TVGN. Based in New Jersey, Tevogen is developing a genetically unmodified T-cell therapy called TVGN 489 for the treatment of COVID-19 in highly vulnerable patient populations such as the elderly, infirm and immunocompromised. Semper Paratus went public in November 2021, raising $345M. More on healthcare SPAC...
